Meeting
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
Authors
Dan T. Vogl
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Dan T. Vogl , Yulia Nefedova , E. Paul Wileyto , Chau T. Nguyen , Cynthia Diaczynsky , Abigail Etzweiler , Inna Strakovsky , Cindy Lin , Eva Bondesson , Helen Tuvesson , Erik Vahtola , Adam D. Cohen , Sandra P. Susanibar-Adaniya , Adam J. Waxman , Alfred L. Garfall , Edward Allen Stadtmauer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04405167
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8042)
DOI
10.1200/JCO.2023.41.16_suppl.8042
Abstract #
8042
Poster Bd #
34
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial.
First Author: Katja Weisel
Poster
2014 ASCO Annual Meeting
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
First Author: David H. Vesole
Poster
2014 ASCO Annual Meeting
A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.
First Author: Thomas G. Martin
Poster
2013 ASCO Annual Meeting
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
First Author: Paul Gerard Guy Richardson